PYPD News and Press, PolyPid Ltd. From 08/10/22

PolyPid press release ( NASDAQ: PYPD ): Q2 GAAP EPS of -$1.23 misses by $0.60 . As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital...

Signed Exclusive L icensing A greement for C ommercialization of D-PLEX 100 in Europe for Potentially O ver $110 M illion in U pfront and M ilestone P ayments , Plus R oyalties on N ...

PolyPid ( NASDAQ: PYPD ) signed an exclusive licensing agreement for its lead drug candidate D-PLEX 100 in Europe with U.K.-based Advanz Pharma ( OTCPK:CXRXF ). D-PLEX 100 is used for preventing surgical site infections (SSIs) in abdominal and car...

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX 100 for the prevention of surgical site infections in abdominal and cardiac surgeries in Europe, lev...

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial r...

Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) --  PolyPid Ltd. (Nasdaq: PYPD) (ȁ...

PETACH TIKVA, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that Dikla Czaczkes Akselbrad, formerly the Company ...

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webi...

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“...

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life S...